Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1980 1
1981 1
1982 2
1983 1
1984 1
1985 2
1986 1
1987 3
1988 4
1989 1
1990 3
1991 6
1992 8
1993 3
1994 3
1995 11
1996 7
1997 6
1998 7
1999 7
2000 2
2001 6
2002 4
2003 10
2004 3
2005 10
2006 4
2007 3
2008 4
2009 2
2010 2
2011 5
2012 2
2013 5
2014 4
2015 2
2016 1
2017 1
2018 4
2020 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Acute Myelomonocytic Leukemia"
Page 1
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. DiNardo CD, et al. Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5. Lancet Haematol. 2020. PMID: 32896301 Free PMC article. Clinical Trial.
BACKGROUND: Venetoclax combined with hypomethylating agents is a new standard of care for newly diagnosed patients with acute myeloid leukaemia (AML) who are 75 years or older, or unfit for intensive chemotherapy. ...The study enrolled older patients (aged >60 years) wi …
BACKGROUND: Venetoclax combined with hypomethylating agents is a new standard of care for newly diagnosed patients with acute myeloid …
Classification of acute leukemia.
[No authors listed] [No authors listed] Ann Intern Med. 1977 Dec;87(6):740-53. doi: 10.7326/0003-4819-87-6-740. Ann Intern Med. 1977. PMID: 337870 Review.
The classification of acute leukemia has almost invariably been based on the morphologic diagnosis into two broad categories: acute lymphocytic and acute myeloid leukemia. ...The high incidence with which chronic myelomonocytic leukemi …
The classification of acute leukemia has almost invariably been based on the morphologic diagnosis into two broad categories: …
Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined.
Elliott MA. Elliott MA. Best Pract Res Clin Haematol. 2006;19(3):571-93. doi: 10.1016/j.beha.2005.07.012. Best Pract Res Clin Haematol. 2006. PMID: 16781489 Review.
Current management decisions are based on small studies or extrapolated from therapeutic strategies that are effective in similar chronic, clonal myeloid disorders. Given the potential for evolution to acute leukemia or progressive refractory leucocytosis or …
Current management decisions are based on small studies or extrapolated from therapeutic strategies that are effective in similar chronic, c …
Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.
Lyle L, Daver N. Lyle L, et al. Am J Manag Care. 2018 Aug;24(16 Suppl):S356-S365. Am J Manag Care. 2018. PMID: 30132679 Free article. Review.
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy that largely impacts the elderly population. ...In addition, despite available therapies, most patients will eventually relapse on, or be refractory to, standard induction therapy, with limi …
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy that largely impacts the elderly population. ...In additi …
Natural history study of patients with familial platelet disorder with associated myeloid malignancy.
Cunningham L, Merguerian M, Calvo KR, Davis J, Deuitch NT, Dulau-Florea A, Patel N, Yu K, Sacco K, Bhattacharya S, Passi M, Ozkaya N, De Leon S, Chong S, Craft K, Diemer J, Bresciani E, O'Brien K, Andrews EJ, Park N, Hathaway L, Cowen EW, Heller T, Ryan K, Barochia A, Nghiem K, Niemela J, Rosenzweig S, Young DJ, Frischmeyer-Guerrerio PA, Braylan R, Liu PP. Cunningham L, et al. Blood. 2023 Dec 21;142(25):2146-2158. doi: 10.1182/blood.2023019746. Blood. 2023. PMID: 37738626
Of 111 patients, 19 were diagnosed with HMs, including myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia, acute lymphoblastic leukemia, and smoldering myeloma. Of those 19, 18 were relapsed or refractory …
Of 111 patients, 19 were diagnosed with HMs, including myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonoc …
Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.
Zhao L, Yang J, Chen M, Xiang X, Ma H, Niu T, Gong Y, Chen X, Liu J, Wu Y. Zhao L, et al. Ann Hematol. 2024 Apr;103(4):1197-1209. doi: 10.1007/s00277-024-05646-7. Epub 2024 Feb 8. Ann Hematol. 2024. PMID: 38329487
Venetoclax (VEN), a BCL-2 inhibitor, has transformed treatment strategies for elderly and unfit acute myeloid leukemia (AML) patients by significantly improving response rates and survival. ...This real-world study examined 162 newly diagnosed (ND) and 85 relapsed/ …
Venetoclax (VEN), a BCL-2 inhibitor, has transformed treatment strategies for elderly and unfit acute myeloid leukemia (AML) p …
Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2013 Feb;88(2):141-50. doi: 10.1002/ajh.23384. Am J Hematol. 2013. PMID: 23349007 Free article. Review.
Differential diagnosis of myelofibrosis should include chronic myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. ...Conventional or experimental drug therapy is reasonable for symptomatic i …
Differential diagnosis of myelofibrosis should include chronic myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic …
Childhood myelodysplasia.
Agarwal BR, Currimbhoy ZE. Agarwal BR, et al. Indian Pediatr. 1994 Jul;31(7):797-806. Indian Pediatr. 1994. PMID: 7890342
There were 15 cases of refractory anemia, one of refractory anemia with excess blasts, 3 of refractory anemia with excess blasts in transformation and 10 cases of chronic myelomonocytic leukemia. ...The disease has an aggressive clinical course …
There were 15 cases of refractory anemia, one of refractory anemia with excess blasts, 3 of refractory anemia with exce …
Hypoplastic myelodysplastic syndrome.
Nand S, Godwin JE. Nand S, et al. Cancer. 1988 Sep 1;62(5):958-64. doi: 10.1002/1097-0142(19880901)62:5<958::aid-cncr2820620519>3.0.co;2-p. Cancer. 1988. PMID: 3409176
Clinical features, hemograms, chromosome analysis, incidence of progression to acute leukemia or aplastic anemia, and survival in each group were compared. Using the French-American-British (FAB) classification, there were seven patients with refractory anemi …
Clinical features, hemograms, chromosome analysis, incidence of progression to acute leukemia or aplastic anemia, and survival …
Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2011 Dec;86(12):1017-26. doi: 10.1002/ajh.22210. Am J Hematol. 2011. PMID: 22086865 Free article. Review.
Differential diagnosis of myelofibrosis should include chronic myelogenous leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. ...Conventional or experimental drug therapy is reasonable for symptomat …
Differential diagnosis of myelofibrosis should include chronic myelogenous leukemia, myelodysplastic syndromes, chronic myelomonoc …
151 results